Induced Pluripotent Stem Cells Production Market Size and Forecast 2034

Induced Pluripotent Stem Cells Production Industry Perspective:

What is the anticipated size of the induced pluripotent stem cells production market during the projection period?

The global induced pluripotent stem cells production market size was worth around USD 1.92 billion in 2025 and is predicted to grow to around USD 4.34 billion by 2034, with a compound annual growth rate (CAGR) of roughly 9.48% between 2026 and 2034.

Request Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global induced pluripotent stem cells production market is estimated to grow annually at a CAGR of around 9.48% over the forecast period (2026-2034)
• In terms of revenue, the global induced pluripotent stem cells production market size was valued at around USD 1.92 billion in 2025 and is projected to reach USD 4.34 billion, by 2034.
• The induced pluripotent stem cells production market is projected to grow at a significant rate due to the rising use of tailored treatments for cancer and chronic conditions.
• Based on the process, the automated induced pluripotent stem cells production segment is expected to generate the highest CAGR during the forecast period.
• Based on the workflow, the characterization/analysis segment will emerge as the fastest-growing segment with a CAGR of 16%, leading the market growth rate.
• Based on the product, the automated platforms segment is projected to generate the highest CAGR of 14.1% during the forecast period.
• Based on the application, regenerative medicine/tissue engineering is expected to generate the fastest CAGR of 12% as investments in regenerative medicine will reach new heights.
• Based on region, North America is projected to dominate the global market during the forecast period.

Induced Pluripotent Stem Cells Production Market: Overview

Induced pluripotent stem cell (iPSC) production refers to using novel techniques and technologies to reprogram mature somatic cells into pluripotent stem cells. They can ultimately differentiate into various body cell types and have applications in drug discovery, disease remodeling, and personalized medicine. iPSCs are produced from an adult patient’s own cells and hence carry a unique genetic code. Induced pluripotent stem cells have emerged as powerful tools in modern healthcare research & development, especially advancements associated with tailored medicine. During the forecast period, demand for induced pluripotent stem cell production is expected to grow due to rising use of tailored treatments for cancer and chronic conditions. In addition, investments in regenerative medicine, accelerated drug discoveries, and technological advancements will aid market growth. However, high capital costs, a limited number of players, and regulatory hurdles will affect market revenue during the forecast period.

Impact of the USA-Israel and Iran war on the induced pluripotent stem cells production market:

The ongoing USA-Israel and Iran war is expected to have a limited and indirect impact on the induced pluripotent stem cells production market. The major impact will be witnessed on raw material transportation costs and disruptions in the pharmaceutical supply chain. However, most countries are expected to continue researching iPSC production as global healthcare demand is expected to grow at an increasing rate.

Induced Pluripotent Stem Cells Production Market: Dynamics

Growth Drivers

How are personalized medical treatments expected to shape the induced pluripotent stem cells production market?

The global induced pluripotent stem cells production market is expected to benefit from the growing use of personalized medicine to treat cancer, chronic conditions, and genetic disorders. According to market analysis, precision medicine has shown three times the efficacy in treating advanced oncological conditions as compared to traditional treatments. Medical professionals can reprogram skin and blood cells from adults into a more versatile stem cell state. They can then use these cells to develop patient-specific tissue types, such as brain cells. The ongoing advancements in precision medicine and its applications across disease types will promote the use of iPSCs in the coming years.

Growing pharmaceutical investments and drug discovery to promote market revenue in the long run

Burdening pressure on the existing healthcare infrastructure has propelled pharmaceutical and biotechnology investments worldwide. National and global healthcare agencies, along with private companies, are investing heavily in stem cell research, regenerative medicine, and iPSC-based systems to develop new therapies. The global induced pluripotent stem cells production market is growing as new drugs and medical therapies are introduced in the healthcare sector.

Restraints

Which are the leading restraints in the induced pluripotent stem cells production industry?

The global induced pluripotent stem cells production industry is projected to be restricted due to high production and maintenance costs and a complex manufacturing process. iPSC production is a novel technique that requires specialized equipment, expert workforce, and advanced facilities. In addition, iPSC production is highly complex and requires years of research and development (R&D). These factors limit the number of players operating in the industry.

Opportunities

Which advancements in the induced pluripotent stem cells production market are expected to create growth opportunities?

The global induced pluripotent stem cells production market is anticipated to create growth opportunities due to ongoing advancements such as automation and robotics, improved cell reprogramming techniques, and gene-editing technologies, among others. In May 2026, FUJIFILM Cellular Dynamics, Inc., a global leader in human-induced iPSC production, announced the opening of its new headquarters in Madison. The new sophisticated facility is expected to quadruple the organization’s iPSC-based research and innovation.

In June 2026, Pluristyx, a leading provider of Research Use Only (RUO) and Good Manufacturing Practice  (GMP) iPSC platform systems, and Made Scientific, Inc., a prominent contract development and manufacturing organization (CDMO), announced a novel partnership. Through the collaboration, the companies are expected to develop next-generation iPSC-derived cell therapies. The rising number of clinical trials and comprehensive regulatory framework will further advance iPSC production in the coming years.

Challenges

Safety concerns and lack of standard regulations challenge industry expansion

The global induced pluripotent stem cell production industry is expected to face challenges from safety concerns, strict regulatory pressure, and a lack of standardized regulations. Genomic instability in iPSCs during the production stage can lead to adverse effects. In addition, current legal rules around iPSC research & development are not only strict but also inconsistent across regions. This creates additional challenges for the industry players planning to expand their presence.

Induced Pluripotent Stem Cells Production Market: Report Scope

Induced Pluripotent Stem Cells Production Market: Segmentation

The global induced pluripotent stem cells production market is segmented based on process, workflow, production, application, and region.

Why will the automated induced pluripotent stem cells production segment lead the induced pluripotent stem cells production industry revenue during the forecast period?

Based on process, the global market segments are automated induced pluripotent stem cells production and manual induced pluripotent stem cells production. In 2025, the highest growth was listed in the manual induced pluripotent stem cells production segment. It accounted for 78% of the global revenue. During the forecast period, automated induced pluripotent stem cells production will generate a higher CAGR of 11.51%, driven by the ongoing use of next-generation robotic and automation technologies in drug discovery and therapy development.

Which will be the fastest-growing workflow during the forecast period in the induced pluripotent stem cells production market?

Based on workflow, the global market is fragmented into cell characterization/analysis, cell culture, and others. In 2025, around 40% of the global revenue was listed in the cell culture segment. During the projection period, characterization/analysis will be the fastest-growing segment, with a CAGR of 16%. An increasing demand for cell purity, quality, density, and safety will drive segmental revenue in the coming years.

Which factors drive demand in the automated platforms segment in the induced pluripotent stem cells production industry?

Based on product, the global induced pluripotent stem cells production industry is divided into automated platforms, consumables/kits, and others. In 2025, the consumables/kits segment held the highest market share at 41%. The automated platforms segment is projected to generate the highest CAGR of 14.1% during the forecast period, driven by rapid automation across pharmaceutical, biotechnology, and healthcare sectors.

What will be the influence of the regenerative medicine/tissue engineering segment on the induced pluripotent stem cells production market?

Based on application, the global market is divided into regenerative medicine/tissue engineering, drug development & discovery, developmental biology, neurological research, and others. The drug development & discovery segment was the highest revenue generator in 2025. It accounted for 44% of the total revenue. During the forecast period, regenerative medicine/tissue engineering is expected to generate the fastest CAGR of 12% as investments in regenerative medicine will reach new heights.

Induced Pluripotent Stem Cells Production Market: Regional Analysis

Why will North America lead the induced pluripotent stem cells production market in the coming years?

The global induced pluripotent stem cells production market is currently led by North America. In 2025, it accounted for 40.67% of the global revenue and will grow at a CAGR of 10.21% during the forecast period. North America is home to one of the world’s leading biotechnology industries. In addition, the presence of pharmaceutical giants investing heavily in next-generation medical therapies will drive regional growth. Advanced research infrastructure, growing clinical trial rate, and mature legal framework will promote growth across North America.

Why will Asia-Pacific generate the fastest CAGR in the induced pluripotent stem cells production market during the forecast period?

Asia-Pacific is expected to emerge as the fastest-growing region in the induced pluripotent stem cells production market with a CAGR of 11.26% during the forecast period. In 2025, it accounted for a considerable share of the global revenue. Growing burden on regional healthcare, increasing demand for personalized medicine, favorable government policies encouraging local drug development, and healthcare expansion will propel revenue in Asia-Pacific. Additionally, iPSC-related technological advancements will ensure sustained regional growth in the coming years.

Induced Pluripotent Stem Cells Production Market: Competitive Analysis

The global induced pluripotent stem cells production market is led by players like:

• Evotec
• Takara Bio
• Axol Bioscience
• Lonza Group
• FUJIFILM Cellular Dynamics
• Thermo Fisher Scientific
• Hitachi
• STEMCELL Technologies
• Fate Therapeutics
• Applied StemCell
• REPROCELL
• Bio-Techne
• Creative Biolabs
• StemCellsFactory III
• Merck KGaA.

What are the latest key trends in the induced pluripotent stem cells production market?

Higher focus on GMP-compliance

Market players are developing GMP-compliant iPSC production, including cell banking, reprogramming, and cryopreservation. This will help companies achieve accelerated clinical trials and commercialization.

Automation across production

The increasing use of automated technologies, from cell culture to quality control, is a prominent market trend. Automated end-to-end manufacturing workflows reduce manufacturing inconsistencies and contamination risks.

The global induced pluripotent stem cells production market is segmented as follows:

By Process

• Automated Induced Pluripotent Stem Cells Production Market
• Manual Induced Pluripotent Stem Cells Production Market

By Workflow

• Cell Characterization/Analysis
• Cell Culture
• Others

By Product

• Automated Platforms
• Consumables/Kits
• Others

By Application

• Regenerative Medicine / Tissue Engineering
• Drug Development & Discovery
• Developmental Biology
• Neurological Research
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America